Reducing mobilization of simian immunodeficiency virus based vectors by primer complementation

Journal of Gene Medicine

Volumn 6, Issue 2, 2004, Pages 147-154

  Grunwald, Thomas ^a   Pedersen, Finn Skou ^b   Wagner, Ralf ^c   Überla, Klaus ^a,d  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Gene transfer; HIV; Lentiviral vector; Mobilization; Primer complementation; SIV

Indexed keywords

LENTIVIRUS VECTOR; PRIMER RNA; TRANSFER RNA; VIRUS DNA; VIRUS VECTOR; GAG PROTEIN; PRIMER DNA; VIRUS ENVELOPE PROTEIN;

ARTICLE; BINDING SITE; CONTROLLED STUDY; GENE MUTATION; GENETIC COMPLEMENTATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; RISK REDUCTION; RNA BINDING; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL GENE THERAPY; WILD TYPE; ANIMAL; GENE DELETION; GENE VECTOR; GENETICS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; DNA PRIMERS; FUSION PROTEINS, GAG-POL; GENE PRODUCTS, ENV; GENETIC VECTORS; HIV-1; HUMANS; SEQUENCE DELETION; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC;

EID: 4644251244     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.479     Document Type: Article

References (31)

1. Naldini L, Blömer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
2. Reiser J, Harmison G, Kluepfel Stahl S, Brady RO, Karlsson S, Schubert M. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci U S A 1996; 93: 15 266-15 271.
3. Arya SK, Zamani M, Kundra P. Human immunodeficiency virus type 2 lentivirus vectors for gene transfer: expression and potential for helper virus-free packaging. Hum Gene Ther 1998; 9: 1371-1380.
4. Schnell T, Foley P, Wirth M, Münch J, Überla K. Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 2000; 11: 439-447.
5. Mangeot PE, Negre D, Dubois B, et al. Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J Virol 2000; 74: 8307-8315.
6. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998; 4: 354-357.
7. Johnston JC, Gasmi M, Lim LE, et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol 1999; 73: 4991-5000.
8. Mitrophanous K, Yoon S, Rohll J, et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 1999; 6: 1808-1818.
9. Bukovsky AA, Song JP, Naldini L. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol 1999; 73: 7087-7092.
10. An DS, Morizono K, Li QX, Mao SH, Lu S, Chen IS. An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol 1999; 73: 7671-7677.
11. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
12. Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998; 72: 8150-8157.
13. Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther 2001; 3: 97-104.
14. Lund AH, Duch M, Lovmand J, Jorgensen P, Pedersen FS. Complementation of a primer binding site-impaired murine leukemia virus-derived retroviral vector by a genetically engineered tRNA-like primer. J Virol 1997; 71: 1191-1195.
15. Yu Q, Morrow CD. Identification of critical elements in the tRNA acceptor stem and T(Psi)C loop necessary for human immunodeficiency virus type 1 infectivity. J Virol 2001; 75: 4902-4906.
16. Yu Q, Morrow CD. Essential regions of the tRNA primer required for HIV-1 infectivity. Nucleic Acids Res 2000; 28: 4783-4789.
17. Hansen AC, Grunwald T, Lund AH, et al. Transfer of primer binding site-mutated simian immunodeficiency virus vectors by genetically engineered artificial and hybrid tRNA-like primers. J Virol 2001; 75: 4922-4928.
18. Kaluz S, Kolble K, Reid KB. Directional cloning of PCR products using exonuclease III. Nucleic Acids Res 1992; 20: 4369-4370.
19. Wagner R, Graf M, Bieler K, et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther 2000; 11: 2403-2413.
20. Reiprich S, Gundlach RB, Fleckenstein B, Überla K. Replication competent chimeric lenti-oncovirus with expanded host cell tropsim. J Virol 1997; 71: 3328-3331.
21. Gundlach BR, Linhart H, Dittmer U, et al. Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin 2. J Virol 1997; 71: 2225-2232.
22. Helseth E, Kowalski M, Gabuzda D, Olshevsky U, Haseltine W, Sodroski J. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol 1990; 64: 2416-2420.
23. Fouchier RAM, Meyer BE, Simon JHM, Fischer U, Malim MH. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J 1997; 16: 4531-4539.
24. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987; 7: 379-387.
25. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, Clavel F. HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994; 241: 651-662.
26. Soneoka Y, Cannon PM, Ramsdale EE, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 1995; 23: 628-633.
27. Leurs C, Jansen M, Pollok KE, et al. Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34(+) cord blood cells. Hum Gene Ther 2003; 14: 509-519.
28. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-666.
29. Mak J, Kleiman L. Primer tRNAs for reverse transcription. J Virol 1997; 71: 8087-8095.
30. Mikkelsen JG, Lund AH, Dybkaer K, Duch M, Pedersen FS. Extended minus-strand DNA as template for R-U5-mediated second-strand transfer in recombinational rescue of primer binding site-modified retroviral vectors. J Virol 1998; 72: 2519-2525.
31. Mikkelsen JG, Lund AH, Kristensen KD, et al. A preferred region for recombinational patch repair in the 5′ untranslated region of primer binding site-impaired murine leukemia virus vectors. J Virol 1996; 70: 1439-1447.